 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||
5 June 2007 | Volume 146 Issue 11 | Pages 797-808
Background: Rheumatoid factor (RF) and autoantibodies against cyclic citrullinated peptide (CCP) are markers that might help physicians diagnose rheumatoid arthritis.
Purpose: To determine whether anti-CCP antibody more accurately identifies patients with rheumatoid arthritis and better predicts radiographic progression than does RF.
Data Sources: MEDLINE through September 2006 and reference lists of retrieved studies and review articles.
Study Selection: Studies in any language that enrolled at least 10 participants and that examined the role of anti-CCP antibody and RF in the diagnosis or prognosis of known or suspected rheumatoid arthritis.
Data Extraction: Two authors independently evaluated studies for inclusion, rated methodological quality, and abstracted relevant data.
Data Synthesis: The DerSimonian–Laird random-effects method was used to summarize sensitivities, specificities, and positive and negative likelihood ratios from 37 studies of anti-CCP antibody and 50 studies of RF. The pooled sensitivity, specificity, and positive and negative likelihood ratios for anti-CCP antibody were 67% (95% CI, 62% to 72%), 95% (CI, 94% to 97%), 12.46 (CI, 9.72 to 15.98), and 0.36 (CI, 0.31 to 0.42), respectively. For IgM RF, the values were 69% (CI, 65% to 73%), 85% (CI, 82% to 88%), 4.86 (CI, 3.95 to 5.97), and 0.38 (CI, 0.33 to 0.44). Likelihood ratios among IgM RF, IgG RF, and IgA RF seemed to be similar. Results from studies of patients with early rheumatoid arthritis were similar to those from all studies. Three of 4 studies found that risk for radiographic progression was greater with anti-CCP antibody positivity than with IgM RF positivity.
Limitations: Many studies had methodological limitations. Studies of RF were heterogeneous and had wide ranges of sensitivity and specificity.
Conclusions: Anti-CCP antibodies are more specific than RF for diagnosing rheumatoid arthritis and may better predict erosivedisease.
Editors' Notes
Context
Contribution
Cautions
Implication
—The Editors
Author and Article Information
From Harvard School of Public Health, Boston, Massachusetts, and Hyogo College of Medicine and Kobe University Graduate School of Medicine, Hyogo, Japan.
Acknowledgments: The authors thank their colleagues from Kobe University Graduate School of Medicine: Yumiko Nobuhara, MD, for language assistance and Yasuko Nakayama for logistic assistance. They also thank Yasushi Kaji, Dokkyo Medical University, Department of Radiology, for methods assistance and Dr. William F. Goldman (MST Editing Company, Baltimore, Maryland) for editorial assistance and preparation of the manuscript.
Grant Support: In part by a Grant-in-Aid for Young Scientists from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and a grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labor and Welfare, Japan.
Potential Financial Conflicts of Interest: Grants received: S. Kumagai (Japanese Ministry of Health).
Requests for Single Reprints: Kunihiro Nishimura, MD, MPH, MS, Department of Health Policy Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02215; e-mail, knishimu{at}hsph.harvard.edu.
Current Author Addresses: Drs. Nishimura and Kuntz: Department of Health Policy Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02215.
Drs. Sugiyama, Kogata, Tsuji, Nakazawa, Kawano, Saigo, Morinobu, and Kumagai: Department of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, 7-5-2 Kusunokicho, Kobe, Hyogo, Japan 650-0017.
Dr. Koshiba: Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo, Japan 663-8501.
Dr. Kamae: Department of Applied Biostatistics, Kobe University Graduate School of Medicine, 7-5-2 Kusunokicho, Kobe, Hyogo, Japan 650-001. REVIEW
Meta-analysis: Diagnostic Accuracy of Anti–Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Y-F Qing, Q-B Zhang, J-G Zhou, G-H Yuan, J Wei, Y Xing, J-P Liu, L Jiang, and J-P Chen The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus Lupus, July 1, 2009; 18(8): 713 - 717. [Abstract] [PDF]
|
|
|
|
 |
|
 T. SOKKA and H. MAKINEN An Excellent Example of an Early Arthritis Clinic -- What Is Its Clinical Value? J Rheumatol, July 1, 2009; 36(7): 1355 - 1356. [Full Text] [PDF]
|
|
|
|
|
|
T. PINCUS and T. SOKKA Quantitative Clinical Rheumatology: "Keep It Simple, Stupid": MDHAQ Function, Pain, Global, and RAPID3 Quantitative Scores to Improve and Document the Quality of Rheumatologic Care J Rheumatol, June 1, 2009; 36(6): 1099 - 1100. [Full Text] [PDF]
|
|
|
|
|
|
S. JACOBSEN, P. GARRED, H. O. MADSEN, N. H.H. HEEGAARD, M. L. HETLAND, K. STENGAARD-PEDERSEN, P. JUNKER, T. LOTTENBURGER, T. ELLINGSEN, L. S. ANDERSEN, et al. Mannose-Binding Lectin Gene Polymorphisms Are Associated with Disease Activity and Physical Disability in Untreated, Anti-Cyclic Citrullinated Peptide-Positive Patients with Early Rheumatoid Arthritis J Rheumatol, April 1, 2009; 36(4): 731 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. MUTLU, M. BICAKCIGIL, D. A. TASAN, A. KAYA, S. YAVUZ, and A. I. OZDEN Comparative Performance Analysis of 4 Different Anti-Citrullinated Protein Assays in the Diagnosis of Rheumatoid Arthritis J Rheumatol, March 1, 2009; 36(3): 491 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M L Hetland, B Ejbjerg, K Horslev-Petersen, S Jacobsen, A Vestergaard, A G Jurik, K Stengaard-Pedersen, P Junker, T Lottenburger, I Hansen, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA) Ann Rheum Dis, March 1, 2009; 68(3): 384 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X Bossuyt, D Coenen, S Fieuws, P Verschueren, R Westhovens, and N Blanckaert Likelihood ratios as a function of antibody concentration for anti-cyclic citrullinated peptide antibodies and rheumatoid factor Ann Rheum Dis, February 1, 2009; 68(2): 287 - 289. [Full Text] [PDF]
|
|
|
|
|
|
D M Lee, R Phillips, E M Hagan, L B Chibnik, K H Costenbader, and P H Schur Quantifying anti-cyclic citrullinated peptide titres: clinical utility and association with tobacco exposure in patients with rheumatoid arthritis Ann Rheum Dis, February 1, 2009; 68(2): 201 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Shmerling Testing for Anti-Cyclic Citrullinated Peptide Antibodies: Is It Time to Set This Genie Free? Arch Intern Med, January 12, 2009; 169(1): 9 - 14. [Full Text] [PDF]
|
|
|
|
|
|
K P Liao, K L Batra, L Chibnik, P H Schur, and K H Costenbader Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis Ann Rheum Dis, November 1, 2008; 67(11): 1557 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Taneja, M. Behrens, E. Basal, J. Sparks, M. M. Griffiths, H. Luthra, and C. S. David Delineating the Role of the HLA-DR4 "Shared Epitope" in Susceptibility versus Resistance to Develop Arthritis J. Immunol., August 15, 2008; 181(4): 2869 - 2877. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Kitahara, K Takagi, Y Kusunoki, S Nishio, T Nozaki, H Inomata, M Takei, S Sawada, and S Kawai Clinical value of second- and third-generation assays of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis Ann Rheum Dis, July 1, 2008; 67(7): 1059 - 1060. [Full Text] [PDF]
|
|
|
|
|
|
G. Damian-Abrego, J Cabiedes, and A. Cabral Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy Lupus, April 1, 2008; 17(4): 300 - 304. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Roubenoff, E. Beckman, M. Weinblatt, N. Shadick, and P. K. Gregersen Biological Significance of Anti-Cyclic Citrullinated Peptide Antibody in Rheumatoid Arthritis Ann Intern Med, March 4, 2008; 148(5): 403 - 403. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Arkfeld Biological Significance of Anti-Cyclic Citrullinated Peptide Antibody in Rheumatoid Arthritis Ann Intern Med, March 4, 2008; 148(5): 403 - 403. [Full Text] [PDF]
|
|
|
|
|
|
K. Nishimura, A. Morinobu, and S. Kumagai Biological Significance of Anti-Cyclic Citrullinated Peptide Antibody in Rheumatoid Arthritis Ann Intern Med, March 4, 2008; 148(5): 403 - 404. [Full Text] [PDF]
|
|
|
|
|
|
A. Finckh and M. H. Liang Anti-Cyclic Citrullinated Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis: Bayes Clears the Haze Ann Intern Med, June 5, 2007; 146(11): 816 - 817. [Full Text] [PDF]
|
|
Read all Rapid Responses
